恩格列净的心血管获益与2型糖尿病患者的肠道菌群及血浆代谢物相关
这项随机、开放标签、3个月、双臂临床试验纳入76例初治2型糖尿病且有心血管疾病风险因素的患者,分别接受恩格列净10 mg/d(n=40)或二甲双胍1700 mg/d(n=36)治疗。两组HbA1c降低程度相似,但仅恩格列净改善心血管疾病风险因素,并重塑肠道菌群、改变血浆代谢物水平。作者认为恩格列净可能是有心血管疾病风险的2型糖尿病患者的更优初始治疗。
要点
- 两组HbA1c降低程度相似,但仅恩格列净组改善心血管疾病风险因素。
- 恩格列净治疗1个月后显著重塑肠道菌群,并维持至试验结束。
- 恩格列净升高鞘磷脂等代谢物,降低甘氨鹅脱氧胆酸、顺乌头酸和尿酸。
核心结论
- 恩格列净可能是有心血管疾病风险的2型糖尿病患者的更优初始治疗;其心血管获益可能与肠道菌群和血浆代谢物的改变有关。
研究设计与样本
- 随机、开放标签、3个月、双臂临床试验,纳入76例初治2型糖尿病且有心血管疾病风险因素的患者,恩格列净10 mg/d组n=40,二甲双胍1700 mg/d组n=36。
主要发现
- 两组HbA1c水平均显著且相似地降低,糖代谢均得到改善。
- 仅恩格列净组改善心血管疾病风险因素。
- 恩格列净治疗1个月后显著重塑肠道菌群,该改变维持至试验结束。
- 恩格列净升高鞘磷脂等血浆代谢物水平,降低甘氨鹅脱氧胆酸、顺乌头酸和尿酸水平。
- 恩格列净升高产短链脂肪酸菌如罗斯氏菌属、真杆菌属和粪杆菌属物种水平,降低若干有害菌包括埃希菌-志贺菌属、嗜胆菌属和Hungatella水平。
临床怎么用
- 作者认为恩格列净可能是有心血管疾病风险的2型糖尿病患者的更优初始治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Cardiovascular benefits of empagliflozin in patients with type 2 diabetes mellitus (T2DM) have been reported; however, the underlying mechanism remains unknown. OBJECTIVE: We hypothesized that the cardiovascular benefits of empagliflozin are associated with altered gut microbiota and plasma metabolites, and that empagliflozin may be used as an initial treatment for patients with T2DM at risk of cardiovascular diseases (CVDs). METHODS: This randomized, open-label, 3-month, 2-arm clinical trial included 76 treatment-naïve patients with T2DM and risk factors for CVD who were treated with either empagliflozin (10 mg/d, n = 40) or metformin (1700 mg/d, n = 36). We investigated changes in clinical parameters related to glucose metabolism and CVD risk factors, gut microbiota using 16S rRNA gene sequencing, and plasma metabolites using LC-MS. RESULTS: We found significant and similar reduction in HbA1c levels and alleviation of glucose metabolism in both groups. However, only empagliflozin improved CVD risk factors. Empagliflozin significantly reshaped the gut microbiota after 1 month of treatment; this alteration was maintained until the end of the trial. Empagliflozin increased the levels of plasma metabolites such as sphingomyelin, but reduced glycochenodeoxycholate, cis-aconitate, and uric acid levels. Concurrently, empagliflozin elevated levels of short-chain fatty acid-producing bacteria such as species from Roseburia, Eubacterium, and Faecalibacterium, and reduced those of several harmful bacteria including Escherichia-Shigella, Bilophila, and Hungatella. CONCLUSION: Empagliflozin may be a superior initial therapy for patients with T2DM at risk of CVDs; its cardiovascular benefits may be associated with shifts in gut microbiota and plasma metabolites.
引用
- Deng X, Zhang C, Wang P, et al. Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes. J Clin Endocrinol Metab. 2022. PMID: 35397165. doi:10.1210/clinem/dgac210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。